Market Overview

Argentum Pharmaceuticals Wins Patent Invalidation Trial Against Patent on Valeant's JUBLIA®

Share:

Argentum Pharmaceuticals Wins Patent Invalidation Trial Against Patent on Valeant's JUBLIA®

PR Newswire

NEW YORK, June 7, 2018 /PRNewswire/ -- On June 6, 2018, the U.S. Patent & Trademark Office (PTO) issued a final written decision in favor of Argentum Pharmaceuticals, finding all claims of U.S. Patent No. 7,214,506 ("'506 patent") to be unpatentable for obviousness.  The '506 patent is listed in the Food & Drug Administration's Orange Book as covering Valeant Pharmaceuticals' JUBLIA® (efinaconazole 10% solution) drug.  According to the Orange Book, the '506 patent will not expire until October 5, 2021.

Argentum Pharmaceuticals. Balancing the rights of pharmaceutical innovators and consumers. (PRNewsFoto/Argentum Pharmaceuticals)

On May 12, 2017, Argentum filed an inter partes review (IPR) petition challenging all claims (claims 1 and 2) of the '506 patent. 

In its final written decision, the Patent Trial & Appeal Board concluded that Argentum "has shown by a preponderance of the evidence that claims 1 and 2 of the '506 patent are unpatentable."

Commenting on the Board's decision, Argentum's CEO Jeffrey Gardner stated:

"Argentum is pleased with the Board's thorough and detailed decision holding all claims of the '506 claims to be unpatentable. This decision once again shows that the IPR process is an efficient and effective tool to obtain expert agency review of Orange Book listed patents that should not have been granted in the first place.

Argentum's core mission is to lower the cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.  The IPR process has been shown to work for the benefit of American patients by improving their access to the high quality, safe, and effective FDA-approved generic alternatives that they deserve."

About Argentum Pharmaceuticals

Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.  http://www.argentumpharmaceuticals.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/argentum-pharmaceuticals-wins-patent-invalidation-trial-against-patent-on-valeants-jublia-300662242.html

SOURCE Argentum Pharmaceuticals

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com